Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 known ✓ | Q99720 | 1/20 | 0.41 |
| ▸ | MAOA known ✓ | P21397 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 2/20 | 0.40 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3299241 | 1.00 | EPHX2 (0.46) | EPHX2L3MBTL1KDM4ECYP3A4MAPT | |
| Hydrochloric Acid SCHEMBL11150761 | 1.00 | EPHX2 (0.46) | EPHX2L3MBTL1KDM4ECYP3A4MAPT | |
| Hydrochloric Acid SCHEMBL8417309 | 1.00 | EPHX2 (0.46) | EPHX2L3MBTL1KDM4ECYP3A4MAPT | |
| Hydrochloric Acid SCHEMBL356747 | 1.00 | EPHX2 (0.46) | EPHX2L3MBTL1KDM4ECYP3A4MAPT | |
| Hydrochloric Acid SCHEMBL9725437 | 1.00 | EPHX2 (0.46) | EPHX2L3MBTL1KDM4ECYP3A4MAPT | |
| Hydrochloric Acid SCHEMBL28716627 | 1.00 | EPHX2 (0.46) | EPHX2L3MBTL1KDM4ECYP3A4MAPT | |
| Hydrochloric Acid SCHEMBL8988138 | 0.98 | EPHX2 (0.45) | EPHX2L3MBTL1KDM4ECYP3A4MAPT | |
| SCHEMBL5606363 | 0.98 | EPHX2 (0.47) | EPHX2L3MBTL1SIGMAR1FAAHDNM1 | |
| SCHEMBL2369686 | 0.98 | EPHX2 (0.47) | EPHX2L3MBTL1SIGMAR1FAAHDNM1 | |
| SCHEMBL2370129 | 0.98 | EPHX2 (0.47) | EPHX2L3MBTL1SIGMAR1FAAHDNM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200245616-A1 | A Disinfectant Composition with Extended Antimicrobial Effects | RUST-OLEUM CORPORATION | 2020-08-06 | — | — | US | claimed |
| EP-3599863-A1 | A DISINFECTANT COMPOSITION WITH EXTENDED ANTIMICROBIAL EFFECTS | Siamons International Inc. (CA) | 2020-02-05 | — | — | EP | claimed |
| WO-2018176118-A1 | A DISINFECTANT COMPOSITION WITH EXTENDED ANTIMICROBIAL EFFECTS | SIAMONS INTERNATIONAL INC. (CA) | 2018-10-04 | — | — | WO | claimed |
| US-20170251666-A1 | ONE-PART SOLID GLUTARALDEHYDE-QUATERNARY AMMONIUM INCLUSION OR OCCLUSION COMPLEXES AND THEIR USES | ECOLAB USA INC. | 2017-09-07 | — | — | US | claimed |
| EP-1884231-A1 | Cosmetic or pharmaceutical composition containing hyaluronic acid | Auriga International S.A. (BE) | 2008-02-06 | — | — | EP | claimed |
| US-6472168-B2 | REMOVING CONTAMINANTS FROM SPERM BY MIXING WITH A CATIONIC SURFACTANT, STAINING THE SPERM, INTRODUCING INTO A FLOW CELL AND IRRADIATING, DETECTING SCATTERED AND FLUORESCENT LIGHT INTENSITIES, SPECIFIYING A REGION OF SPERM MASS AND COUNTING | SYSMEX CORPORATION (JP) | 2002-10-29 | — | — | US | claimed |
| US-20010024806-A1 | Process for counting sperms and reagent therefor | SYSMEX CORPORATION | 2001-09-27 | — | — | US | claimed |
| CN-119998425-A | Use of a composition for selectively etching silicon and method for selectively etching silicon | 巴斯夫欧洲公司 | 2025-05-13 | — | — | CN | disclosed |
| CN-119563000-A | Method for etching polysilicon | 恩特格里斯公司 | 2025-03-04 | — | — | CN | disclosed |
| CN-118234830-A | Selective wet etching composition and method | 恩特格里斯公司 | 2024-06-21 | — | — | CN | disclosed |
| CN-113164361-B | Personal care compositions | 高露洁-棕榄公司 | 2024-04-02 | — | — | CN | disclosed |
| CN-113950520-B | Liquid composition for selective removal of polysilicon relative to p-doped silicon and silicon-germanium during semiconductor device fabrication | 弗萨姆材料美国有限责任公司 | 2024-03-01 | — | — | CN | disclosed |
| CN-117616544-A | Use of a composition for selectively etching silicon and method for selectively etching silicon | 巴斯夫欧洲公司 | 2024-02-27 | — | — | CN | disclosed |
| US-20010036586-A1 | Toner and manufacturing method thereof | SHARP KABUSHIKI KAISHA (JP) | 2001-11-01 | — | — | US | disclosed |
| US-20010024806-A1 | Process for counting sperms and reagent therefor | SYSMEX CORPORATION | 2001-09-27 | — | — | US | disclosed |
| EP-1003527-A1 | POLYNUCLEOTIDE COMPOSITIONS | SUPRATEK PHARMA, INC. (CA) | 2000-05-31 | — | — | EP | disclosed |
| WO-1999006055-A1 | POLYNUCLEOTIDE COMPOSITIONS | SUPRATEK PHARMA INC. (CA) | 1999-02-11 | — | — | WO | disclosed |
| EP-0028511-B1 | CEPHALOSPORINS, PROCESSES FOR THEIR PREPARATION AND MICROORGANISMS CAPABLE OF THEIR PRODUCTION | GLAXO GROUP LIMITED (GB) | 1984-04-11 | — | — | EP | disclosed |
| US-4379920-A | CEPHAMYCIN DERIVATIVE | GLAXO GROUP LIMITED (GB) | 1983-04-12 | — | — | US | disclosed |
| EP-0028511-A1 | Cephalosporins, processes for their preparation and microorganisms capable of their production | GLAXO GROUP LIMITED (GB) | 1981-05-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170251666-A1 | ONE-PART SOLID GLUTARALDEHYDE-QUATERNARY AMMONIUM INCLUSION OR OCCLUSION COMPLEXES AND THEIR USES | GLUL, OTUB1, OGDH | SIGMAR1 2862/4885MAOA 2687/4885EPHX2 4280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.